CD274 and non-small cell lung carcinoma: Recently, immunotherapeutic strategies based on the use of monoclonal antibodies (mAbs) engaging and blocking the programmed cell death−1 (PD-1) receptor (nivolumab and pembrolizumab) or its ligand PD-L1 (atezolizumab) have shown durable clinical benefits in patients with advanced NSCLC (3–6).